Literature DB >> 28123855

microRNA-454 shows anti-angiogenic and anti-metastatic activity in pancreatic ductal adenocarcinoma by targeting LRP6.

Yue Fan1, Chenye Shi2, Tianyu Li1, Tiantao Kuang2.   

Abstract

Our previous work has shown that microRNA-454 (miR-454) can inhibit the growth of pancreatic ductal adenocarcinoma (PDAC) by blocking the recruitment of bone marrow-derived macrophages. In the present study, we aimed to explore its role in the proliferation, invasion, and pro-angiogenic activity of PDAC cells in vitro and lung metastasis in vivo. PANC-1 and MiaPaCa-2 cells were transfected with a miR-454-expressing plasmid and tested for cell proliferation, colony formation, cell cycle distribution, invasion, and pro-angiogenic activity. The target gene(s) that mediated the action of miR-454 was identified. The effect of miR-454 overexpression on lung metastasis of PDAC was evaluated in nude mice. Of note, overexpression of miR-454 significantly inhibited PDAC cell proliferation and colony formation and arrests PDAC cells at the G2/M phase. Decreased invasiveness was observed in miR-454-overexpressing PDAC cells. Conditioned media from miR-454-overexpressing PANC-1 cells contained lower levels of vascular endothelial growth factor and had reduced capacity to induce endothelial cell tube-like structure formation. Mechanistically, miR-454 was found to target the mRNA of LRP6 and inhibit the activation of Wnt/β-catenin signaling in PDAC cells. Ectopic expression of LRP6 significantly reversed the suppressive effects of miR-454 on PDAC cells. In vivo studies confirmed that miR-454-overexpressing PANC-1 cells formed significantly less lung metastases than control cells. Altogether, miR-454 functions as a suppressor in tumor growth, angiogenesis, and metastasis in PDAC, likely through downregulation of LRP6.

Entities:  

Keywords:  Angiogenesis; LRP6; growth; metastasis; microRNA-454; pancreatic cancer

Year:  2017        PMID: 28123855      PMCID: PMC5250688     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  24 in total

1.  Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance.

Authors:  Zhongwei Cao; Bi-Sen Ding; Peipei Guo; Sharrell B Lee; Jason M Butler; Stephanie C Casey; Michael Simons; Wayne Tam; Dean W Felsher; Koji Shido; Arash Rafii; Joseph M Scandura; Shahin Rafii
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

2.  LRP5/6 directly bind to Frizzled and prevent Frizzled-regulated tumour metastasis.

Authors:  Dan-Ni Ren; Jinxiao Chen; Zhi Li; Hongwei Yan; Yan Yin; Da Wo; Jiankang Zhang; Luoquan Ao; Bo Chen; Takashi K Ito; Yihan Chen; Zhongmin Liu; Yongyong Li; Jianhua Yang; Xiaoling Lu; Yi Peng; Linghui Pan; Yongxiang Zhao; Shangfeng Liu; Weidong Zhu
Journal:  Nat Commun       Date:  2015-04-22       Impact factor: 14.919

3.  CD44 functions in Wnt signaling by regulating LRP6 localization and activation.

Authors:  M Schmitt; M Metzger; D Gradl; G Davidson; V Orian-Rousseau
Journal:  Cell Death Differ       Date:  2014-10-10       Impact factor: 15.828

4.  VEGF and Id-1 in pancreatic adenocarcinoma: prognostic significance and impact on angiogenesis.

Authors:  D Georgiadou; T N Sergentanis; S Sakellariou; G M Filippakis; F Zagouri; D Vlachodimitropoulos; T Psaltopoulou; A C Lazaris; E Patsouris; G C Zografos
Journal:  Eur J Surg Oncol       Date:  2014-01-18       Impact factor: 4.424

5.  miR-454 is down-regulated in osteosarcomas and suppresses cell proliferation and invasion by directly targeting c-Met.

Authors:  Guangfeng Niu; Bin Li; Jianmin Sun; Li Sun
Journal:  Cell Prolif       Date:  2015-04-16       Impact factor: 6.831

6.  Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.

Authors:  C C Solorzano; C H Baker; C J Bruns; J J Killion; L M Ellis; J Wood; I J Fidler
Journal:  Cancer Biother Radiopharm       Date:  2001-10       Impact factor: 3.099

7.  Calcipotriol Targets LRP6 to Inhibit Wnt Signaling in Pancreatic Cancer.

Authors:  Michael D Arensman; Phillip Nguyen; Kathleen M Kershaw; Anna R Lay; Claire A Ostertag-Hill; Mara H Sherman; Michael Downes; Christopher Liddle; Ronald M Evans; David W Dawson
Journal:  Mol Cancer Res       Date:  2015-07-29       Impact factor: 5.852

8.  Dauricine inhibits insulin-like growth factor-I-induced hypoxia inducible factor 1alpha protein accumulation and vascular endothelial growth factor expression in human breast cancer cells.

Authors:  Xu-dong Tang; Xin Zhou; Ke-yuan Zhou
Journal:  Acta Pharmacol Sin       Date:  2009-04-06       Impact factor: 6.150

Review 9.  Current concepts and novel targets in advanced pancreatic cancer.

Authors:  Patrick Michl; Thomas M Gress
Journal:  Gut       Date:  2012-10-30       Impact factor: 23.059

10.  Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines.

Authors:  Mitsuharu Fukasawa; Murray Korc
Journal:  Clin Cancer Res       Date:  2004-05-15       Impact factor: 12.531

View more
  20 in total

1.  Circulating pro-angiogenic and anti-angiogenic microRNA expressions in patients with acute ischemic stroke and their association with disease severity.

Authors:  Fuqiang Jin; Jie Xing
Journal:  Neurol Sci       Date:  2017-09-05       Impact factor: 3.307

2.  LncRNA XIST interacts with miR-454 to inhibit cells proliferation, epithelial mesenchymal transition and induces apoptosis in triple-negative breast cancer.

Authors:  Xiaohua Li; Lili Hou; Lei Yin; Shuai Zhao
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

3.  Long noncoding RNA LINC00657 enhances the malignancy of pancreatic ductal adenocarcinoma by acting as a competing endogenous RNA on microRNA-433 to increase PAK4 expression.

Authors:  Shasha Bi; Yan Wang; Hu Feng; Qingchang Li
Journal:  Cell Cycle       Date:  2020-03-01       Impact factor: 4.534

Review 4.  Pancreatic Ductal Adenocarcinoma: MicroRNAs Affecting Tumor Growth and Metastasis in Preclinical In Vivo Models.

Authors:  Ulrich H Weidle; Fabian Birzele; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2019 Nov-Dec       Impact factor: 4.069

5.  miR-19b-3p promotes human pancreatic cancer Capan-2 cells proliferation by targeting phosphatase and tension homolog.

Authors:  Meiyi Song; Mengxue Sun; Lu Xia; Wei Chen; Changqing Yang
Journal:  Ann Transl Med       Date:  2019-06

6.  LncRNA HOTAIR acts a competing endogenous RNA to control the expression of notch3 via sponging miR-613 in pancreatic cancer.

Authors:  Huihua Cai; Jie Yao; Yong An; Xuemin Chen; Weibo Chen; Di Wu; Boyang Luo; Yong Yang; Yong Jiang; Donglin Sun; Xiaozhou He
Journal:  Oncotarget       Date:  2017-05-16

7.  TSPAN1 promotes autophagy flux and mediates cooperation between WNT-CTNNB1 signaling and autophagy via the MIR454-FAM83A-TSPAN1 axis in pancreatic cancer.

Authors:  Cefan Zhou; Yanyan Liang; Li Zhou; Yanan Yan; Nanxi Liu; Rui Zhang; Yuan Huang; Ming Wang; Yongfei Tang; Declan William Ali; Yefu Wang; Marek Michalak; Xing-Zhen Chen; Jingfeng Tang
Journal:  Autophagy       Date:  2020-10-22       Impact factor: 16.016

Review 8.  Angiogenesis-related non-coding RNAs and gastrointestinal cancer.

Authors:  Zahra Sadat Razavi; Kasra Asgarpour; Maryam Mahjoubin-Tehran; Susan Rasouli; Haroon Khan; Mohammad Karim Shahrzad; Michael R Hamblin; Hamed Mirzaei
Journal:  Mol Ther Oncolytics       Date:  2021-05-15       Impact factor: 7.200

Review 9.  MicroRNAs in cancer metastasis and angiogenesis.

Authors:  Weiyang Lou; Jingxing Liu; Yanjia Gao; Guansheng Zhong; Danni Chen; Jiaying Shen; Chang Bao; Liang Xu; Jie Pan; Junchi Cheng; Bisha Ding; Weimin Fan
Journal:  Oncotarget       Date:  2017-12-11

Review 10.  MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers.

Authors:  Yixin Yang; Christopher Alderman; Ayoub Sehlaoui; Yuan Xiao; Wei Wang
Journal:  Can J Gastroenterol Hepatol       Date:  2018-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.